UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000053552
Receipt number R000061111
Scientific Title Research aimed at elucidating the relationship between viral load and mucosal antibody in influenza
Date of disclosure of the study information 2024/02/12
Last modified on 2024/02/06 13:50:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigation of the relationship between influenza virus and antibodies in nasal swabs

Acronym

The relationship between influenza virus and antibodies

Scientific Title

Research aimed at elucidating the relationship between viral load and mucosal antibody in influenza

Scientific Title:Acronym

The relationship between viral load and mucosal antibody in influenza

Region

Japan


Condition

Condition

Influenza

Classification by specialty

Pneumology Infectious disease Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to clarify the threshold value of mucosal antibody titer required to suppress virus shedding.

Basic objectives2

Others

Basic objectives -Others

the relationship between viral load and mucosal antibody

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Threshold value based on logistic regression and ROC analysis using specific antibody titer against influenza virus antigen and success/failure of virus isolation test

Key secondary outcomes

Sensitivity, specificity, and ROC-AUC were determined by logistic regression and ROC analysis using specific antibody titers against influenza virus antigens and the success or failure of virus isolation tests.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

Nasopharyngeal swab collection

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1) Persons who have completed junior high school or are over 16 years old and under 80 years old at the time of obtaining consent
2) Patients with a positive influenza rapid diagnostic test (RAT) performed using a nasal cavity or nasopharyngeal swab on the day of consent acquisition
3) Subjects who have received sufficient explanation and informed written consent of their own free will to participate in this study.

Key exclusion criteria

Persons who fall under any of the following
1)Patients who have received anti-influenza virus drugs within the past 7 days
2) Other persons deemed unsuitable by the research director

Target sample size

500


Research contact person

Name of lead principal investigator

1st name Kohtaro
Middle name
Last name Fujihashi

Organization

Chiba University Hospital

Division name

Department of Human Mucosal Vaccinology

Zip code

260-8670

Address

1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670 Japan

TEL

043-222-7171

Email

kfujihashi@chiba-u.jp


Public contact

Name of contact person

1st name Morio
Middle name
Last name Nagira

Organization

Chiba University Hospital

Division name

Department of Human Mucosal Vaccinology

Zip code

260-8670

Address

1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670 Japan

TEL

043-222-7171

Homepage URL


Email

morio.nagira@shionogi.co.jp


Sponsor or person

Institute

Chiba University Hospital

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development (AMED)

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Shionogi Co. Ltd.
The National Institute of Infectious Diseases

Name of secondary funder(s)

Shionogi Co. Ltd.


IRB Contact (For public release)

Organization

Chiba University Hospital Observational Research Ethics Review Committee

Address

1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8677 Japan

Tel

043-222-7171

Email

hsp-kansaturinri@chiba-u.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人 緑風会 みどりクリニック(長崎県)、医療法人社団誠和会 藤木内科外科クリニック(宮崎県)、医療法人ロングウッド 前田クリニック(大阪府)、かめざわクリニック(愛知県)、医療法人 光仁会 たかはし内科(神奈川県)、医療法人社団 たむら医院(東京都)、久保クリニック(神奈川県)、医療法人 慈公会 公平病院(埼玉県)、佐藤クリニック(東京都)、医療法人社団 三友会 彩のクリニック(埼玉県)、医療法人 柴崎内科小児科医院(宮城県)、
医療法人社団 弘惠会 杉浦医院(埼玉県)、社会医療法人 恵和会 西岡病院(北海道)、和田耳鼻咽喉科(神奈川県)、たしろ代謝内科クリニック(福岡県)、万代メディカルクリニック(新潟県)/ Midori Clinic(Nagasaki Pref.)、Fujiki Medical and Surgical Clinic(Miyazaki Pref.)、Maeda Clinic(Osaka Pref.)、Kamezawa Clinic(Aichi Pref.)、Takahashi Internal medicine Clinic(Kanagawa Pref.)、Tamura Clinic(Tokyo)、Kubo Clinic(Kanagawa Pref.)、Kodaira Hospital(Saitama Pref.)、Sato Clinic(Tokyo)、Saino Clinic(Saitama Pref.)、Shibasaki Internal medicine and Pediatrics Clinic(Miyagi Pref.)、Sugiura Clinic(Saitama Pref.)、Nishioka Hospital(Hokkaido)、Wada E.N.T Clinic(Kanagawa Pref.)、Tashiro Endocrinology Clinic(Fukuoka Pref.)、Bandai Medical Clinic(Niigata Pref.)


Other administrative information

Date of disclosure of the study information

2024 Year 02 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2024 Year 01 Month 31 Day

Date of IRB


Anticipated trial start date

2024 Year 02 Month 13 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 02 Month 06 Day

Last modified on

2024 Year 02 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061111